Publication | Closed Access

A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure–Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial)

OncologyGastrointestinal OncologyUnbound RegorafenibMetronomic TherapyPharmacologyMetastatic Colorectal CancerReset TrialDrug MonitoringPharmacotherapyAnti-cancer AgentMedicinePharmacodynamic Modeling